Prostate cancer care often begins with a number. For Patient A, a 68-year-old man, the number is an elevated prostate-specific antigen (PSA) level found during routine screening. He feels well. He has no symptoms. But further evaluation leads to a diagnosis of low-risk prostate cancer. His first question is direct: “Do I need surgery?”
For Patient B, age 75, the story begins differently. He presents with persistent back pain. His workup shows metastatic prostate cancer. His question is not whether treatment is needed, but how quickly it can begin.
Healthcare teams, including oncology nurses, have these types of conversations with patients every day during the shared decision-making process. Oncology nurses frequently have to help patients with varying health literacy levels understand what a test result means, what happens next, and whether treatment is truly necessary. Thus, they are frontline providers helping transform a diagnosis from a frightening label into a care plan.
These two hypothetical patients also show the central tension in prostate cancer care. Although both men have prostate cancer, they are facing very different situations. Patient A has prostate cancer that may never cause symptoms or affect his lifespan. Patient B has prostate cancer that has already spread and requires prompt treatment. That difference matters because prostate cancer is common. In the United States, approximately 1 in 8 men will be diagnosed with prostate cancer during their lifetime.1,2 Yet the diagnosis can mean very different things depending on the characteristics of the disease.
Most prostate cancers arise from glandular cells within the prostate, but they do not all behave the same way. Some are slow growing and may be safely monitored for years. Others are more aggressive and can progress locally or spread to distant sites such as bone.1,2 As a result, the clinical challenge is not simply finding prostate cancer. It is understanding the level of risk and matching care to that risk.
This is the journey that patients typically follow after diagnosis and the journey that oncology nurses help navigate every day. From screening and further evaluation to risk assessment, treatment selection, survivorship, and ongoing monitoring, each step is designed to answer the same question: Is this patient receiving too much treatment, too little treatment, or the right amount of treatment? The remainder of this article explores that question through the author-derived Treatment Intensification and Personalization Pathway (TIPP) framework, conceptualized solely as an oncology nurse educational tool (Figure).1,2
TIPP is an author-derived educational framework designed to help oncology nurses organize patient education, navigation, and shared decision-making across the prostate cancer continuum (Figure). Adapted primarily from National Comprehensive Cancer Network (NCCN) screening and prostate cancer recommendations and informed by the latest European Society for Medical Oncology (ESMO) guidance, TIPP reflects contemporary risk-adapted treatment principles that are broadly consistent across major international guidelines. Where substantial concordance exists between NCCN and ESMO recommendations, both sources were used to reinforce key management concepts; ESMO guidance also informed selected aspects of treatment intensification, treatment sequencing, and care personalization. TIPP provides a nursing-facing model for understanding how clinical risk, patient factors, and evolving disease status influence treatment decisions over time.1-3
Although prostate cancer pathways are often presented as algorithms, patients rarely experience care as a straight line. One patient may move from screening to active surveillance, later require definitive local treatment, and then enter long-term follow-up. Another may present with symptomatic metastatic disease and need prompt systemic treatment. TIPP helps nurses interpret these different trajectories while maintaining focus on a central question: Is the patient receiving the right level of care, for the right reason, at the right time?
The framework begins with screening and further evaluation, where the goal is to identify clinically significant disease while limiting unnecessary tests and treatment. After diagnosis, risk stratification becomes the main decision point. Tumor features and disease extent must be considered alongside symptoms, life expectancy, physiologic fitness, comorbidities, treatment tolerance, access to care, and patient priorities. These factors may support active surveillance, standard local treatment, multimodality care, or systemic treatment intensification.1-3
Shared decision-making anchors TIPP. Recommendations can seem counterintuitive to patients: one person may be advised to defer treatment despite a cancer diagnosis, whereas another may be offered several therapies at once following consultations with the care team. Oncology nurses help patients understand why these recommendations differ, identify what matters most to them, and prepare for trade-offs involving cancer control, function, symptoms, treatment burden, and quality of life. This work goes beyond giving information. It includes assessing understanding, correcting misconceptions, setting expectations, identifying barriers, and communicating concerns to the multidisciplinary team.
Put another way, TIPP is dynamic rather than linear. Disease biology can change, treatment toxicities can alter what is feasible, and personal goals or support systems may shift. A patient may remain on surveillance, move toward treatment, require a dose or regimen adjustment, or re-enter active care after recurrence. The nursing contribution is therefore longitudinal: repeated assessment, timely escalation of concerns, adherence support, symptom triage, advocacy, and coordination across settings.
TIPP does not replace clinical guidelines or professional judgment. Its value lies in translating risk-adapted recommendations into a practical nursing approach that connects clinical decisions with the patient’s lived experience. The sections that follow apply the framework across screening, diagnosis, treatment selection, long-term follow-up, supportive care, and survivorship.
As shown in the Figure, screening is the first entry point into the TIPP framework. NCCN patient guidance states that average-risk individuals generally begin prostate cancer screening discussions at age 45, while those with higher-risk features should begin discussions at age 40. Higher-risk features include Black/African American ancestry, family history of prostate cancer, inherited genetic changes, and Agent Orange exposure. NCCN guidance also notes that many individuals can safely stop screening around age 75, although very healthy individuals with a life expectancy of 10 years or more may still consider screening.1
This is where an oncology nurse likely enters the TIPP pathway. Patient A’s screening led to early detection. Patient B’s pathway did not. One patient entered care through a screening result. The other entered through symptoms of advanced disease.
A key nursing responsibility at this stage is explanation. An elevated PSA is not necessarily a diagnosis. It may be a signal that more information is needed. PSA can increase for reasons other than cancer, including age, enlarged prostate, urinary tract infection, inflammation, and some medications.1 Oncology nurses or other nursing colleagues can reduce anxiety by helping patients understand that the next step is not always biopsy or treatment.
After an elevated PSA, NCCN patient guidance recommends further evaluation before biopsy in many cases. This may include repeating the PSA, assessing for noncancer causes, and using magnetic resonance imaging (MRI), ideally multiparametric MRI, before biopsy when appropriate. MRI can help identify aggressive disease and may help some patients avoid unnecessary biopsy. Biopsy remains the only way to confirm prostate cancer.1
For Patient A, this process may confirm low-risk disease. For Patient B, diagnostic workup may confirm metastatic disease. The same pathway can therefore lead to very different treatment decisions. Along with other members of the multidisciplinary team, the oncology nurse helps both patients understand that evaluation is not simply about finding cancer. It is about understanding whether the disease is potentially lethal.
Once prostate cancer is diagnosed, risk stratification becomes the TIPP inflection point. NCCN risk categories help determine whether care should move toward de-intensification, standard local treatment, or intensification.2
For Patient A, low-risk disease points toward de-intensification. This often means active surveillance rather than immediate surgery or radiation therapy. To many patients, that feels counterintuitive. Patient A hears “cancer” and expects action.
The oncology nurse can help explain that active surveillance is not doing nothing. It is structured follow-up designed to avoid unnecessary side effects while still watching carefully for change. The oncology nurse might say, “Your team is not ignoring the cancer. They are watching it closely because treating it now may cause more harm than benefit.” This kind of plain-language explanation can help patients accept surveillance as active care.
For patients with intermediate-risk disease, decisions may be more complex. Some may consider surgery, radiation therapy, or observation-based approaches depending on risk features, life expectancy, baseline urinary and sexual function, and patient goals. Patients with regional disease may need multimodality treatment. Patients with recurrent or metastatic disease may need systemic therapy, imaging, symptom management, and long-term monitoring.2
In this middle ground, oncology nurses often become decision interpreters. They help patients understand trade-offs: cancer control versus urinary, bowel, sexual, emotional, financial, and functional effects. Nurses also identify barriers that may not appear during a physician visit, such as transportation problems, medication confusion, fear of side effects, or low health literacy.
For Patient B, the pathway moves in the opposite direction. His metastatic disease requires treatment intensification.
Because Patient B is 75, treatment planning should include an assessment of physiologic fitness, not age alone. ESMO recommends geriatric screening and/or geriatric assessment for all older patients, defined as those aged 65 years or older, before systemic therapy.3 The guideline does not specify a particular frailty tool in the main recommendations.
For oncology nurses, the practical point is to help assess function, falls risk, comorbidities, medications, cognition, nutrition, caregiver support, transportation, and the patient’s ability to follow a complex treatment plan. The goal is not to deny therapy because of age. The goal is to identify vulnerabilities that can be addressed before treatment begins.
Contemporary treatment intensification involves more than androgen deprivation therapy (ADT) alone. ESMO states that ADT remains the backbone of treatment, but all patients with metastatic castration-sensitive prostate cancer are potential candidates for additional agents alongside ADT, including at minimum an androgen receptor pathway inhibitor (ARPI), unless major contraindicating comorbidities are present. Recommended ARPI options in ESMO guidance include abiraterone, apalutamide, darolutamide, and enzalutamide. For selected patients with de novo high-volume disease who are fit for chemotherapy, triplet therapy with ADT, docetaxel, and an ARPI might be feasible.3
Treatment intensification means more than starting therapy from the perspective of an oncology nurse. It means preparing patients for longer treatment courses, more laboratory monitoring, more appointments, and more adverse-effect assessment. Nurses help patients understand why additional therapy may be recommended, what symptoms to report, how to take oral medications, and when to call the care team.
ESMO identifies several adverse effects that are important for nursing assessment. Docetaxel can increase the risk of myelosuppression, febrile neutropenia, fatigue, alopecia, diarrhea, neuropathy, and peripheral edema. Cabazitaxel is associated with myelosuppression, including febrile neutropenia, and diarrhea. In older or frail patients receiving taxanes, ESMO states that primary prophylaxis with granulocyte colony-stimulating factor may be considered to prevent febrile neutropenia.3
ESMO also reports treatment-specific adverse effects relevant to patient teaching. Abiraterone-prednisone is associated with hypokalemia, hypertension, edema, and cardiac events. Enzalutamide is associated with fatigue or asthenia and hypertension. Lutetium-177 prostate-specific membrane antigen-617 may cause fatigue, dry mouth, nausea, anemia, and thrombocytopenia. Radium-223 may cause thrombocytopenia and diarrhea.3
These details reinforce the nurse’s role in symptom triage, medication review, laboratory follow-up, and timely communication with the oncology team.
As prostate cancer care becomes increasingly individualized, biomarker testing can be viewed as an extension of risk stratification within the TIPP framework. Molecular information may clarify hereditary cancer risk and inform future treatment selection. ESMO recommends germline testing for patients with metastatic castration-sensitive prostate cancer. In metastatic castration-resistant prostate cancer, ESMO recommends genomic testing for alterations in breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2), cyclin-dependent kinase 12 (CDK12), and partner and localizer of BRCA2 (PALB2) at a minimum, ideally before the first treatment of metastatic castration-resistant disease. ESMO also recommends mismatch repair deficiency testing for all patients with metastatic castration-resistant prostate cancer after ARPI treatment.3
This testing can affect future treatment options, including poly (ADP-ribose) polymerase inhibitor therapy for selected patients.3 Nurses frequently help patients understand why testing is being ordered, coordinate referrals, reinforce family counseling recommendations, and address concerns about hereditary cancer risk. This is a natural extension of nursing navigation.
TIPP extends beyond treatment into long-term follow-up, survivorship, and supportive care, recognizing that treatment-related effects and patient priorities often evolve long after an initial decision. Patient A’s long-term management may involve active surveillance, regular reassessment, and the psychological burden of living with untreated cancer. Patient B’s course may involve prolonged systemic treatment, fatigue, pain control, bone health needs, and coordination across specialties.
Survivorship is not a passive phase. In the first months after diagnosis or treatment initiation, nurses confirm understanding, assess symptoms and distress, reconcile medications, and reinforce follow-up. During the first year, they monitor response and early toxicity. Over the next several years, they help patients manage function, recurrence concerns, sexual health, bone health, cardiovascular risk, emotional distress, and return to daily life.
ESMO supportive care recommendations are especially relevant for patients receiving ADT. ESMO recommends exercise therapy combining aerobic and resistance exercises, supervised for at least 12 weeks and then continued without supervision. Bone mineral density assessment by dual-energy x-ray absorptiometry can be considered, especially for patients with additional risk factors, and can be repeated after 12 to 18 months. Bisphosphonates or denosumab are recommended for patients with low bone mineral density or previous osteoporotic fractures. ESMO recommends daily calcium intake of 700 to 1200 mg, preferably through diet, maintaining serum vitamin D levels above 50 nmol/L, and vitamin D supplementation of 800 IU daily for patients older than 50 years.3
Cardiovascular health should be monitored in all patients receiving ADT, particularly those with pre-existing cardiovascular conditions. ESMO recommends referral to a cardiology expert for patients at high cardiovascular risk when ADT is being considered or started.3
For patients with metastatic castration-resistant prostate cancer and bone metastases, ESMO recommends a bone-protecting agent, such as denosumab or zoledronic acid, given with anticancer treatment. Vitamin D and calcium supplementation are recommended before starting a bone-protecting agent and throughout treatment, with serum calcium monitoring. Dental evaluation is recommended before starting a bone-protecting agent, and treatment should be stopped at least intermittently if invasive dental procedures are planned. ESMO also recommends reviewing bone-protecting therapy after 2 to 3 years because of the cumulative risk of osteonecrosis of the jaw.3
Palliation is also part of treatment. ESMO recommends single-fraction external beam radiation therapy for palliation of painful, uncomplicated bone metastases. If metastatic spinal cord compression is suspected, ESMO recommends whole-spine MRI as soon as possible, within 24 hours, at a center with direct access to appropriate imaging. For patients with single-site metastatic spinal cord compression, less than 48 hours of paraplegia, and life expectancy of at least 3 months, urgent decompressive surgery followed by radiation therapy is recommended; if surgery is not performed, urgent radiation therapy is recommended. High-dose steroids are recommended when symptoms occur. Medical optimization of bladder function is also recommended to support quality of life.3
Perhaps the most distinctive aspect of TIPP is that it assumes change rather than stability. Clinical risk is not fixed at diagnosis; it must be reassessed as disease status, treatment tolerance, functional capacity, and patient goals evolve. A patient may move from surveillance to treatment when disease changes, require treatment modification because of toxicity or progression, or re-enter active treatment after recurrence.
Ongoing follow-up is therefore central to TIPP. In metastatic castration-sensitive prostate cancer, ESMO recommends clinical assessment, PSA testing, blood counts, and potentially imaging every 3 to 6 months after approximately 6 months of treatment, with more frequent monitoring when clinically needed. Imaging may be performed at the same frequency as PSA testing or once at 6 months and then repeated with PSA rise or clinical progression. Serum testosterone assessment is recommended to evaluate ADT effectiveness and detect castration resistance, particularly if PSA rises. In metastatic castration-resistant prostate cancer, ESMO states that clinical monitoring with PSA measurements and imaging every 3 to 6 months, or more often as needed, may be recommended.3
Nurses often notice changes before they appear in test results. A patient may report new pain, worsening fatigue, falls, missed medication doses, urinary symptoms, or emotional distress. These findings can signal toxicity, progression, functional decline, or unmet supportive care needs.
Patient A and Patient B show opposite ends of the prostate cancer spectrum. One risks receiving too much treatment. The other risks receiving too little, too late. The oncology nurse helps close that gap by translating risk, supporting shared decision-making, monitoring harm, managing symptoms, and keeping patients connected to care.
In practice, successful prostate cancer care is not about detecting more cancer or giving more treatment. It is about ensuring that every patient receives the right treatment, at the right time, for the right reason.
The author used the AI tool, Claude, for figure design and grammar checks.
To sign up for our newsletter or print publications, please enter your contact information below.
